INNATE PHARMA SA (IPHA): Price and Financial Metrics
INNATE PHARMA SA (IPHA)
Today's Latest Price: $5.16 USD
Updated Nov 24 4:00pm
Add IPHA to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
IPHA Stock Summary
- IPHA's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.47 -- higher than merely 6.08% of US-listed equities with positive expected earnings growth.
- Innate Pharma SA's stock had its IPO on October 18, 2019, making it an older stock than just 0.76% of US equities in our set.
- With a year-over-year growth in debt of 309.54%, Innate Pharma SA's debt growth rate surpasses 94.83% of about US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to Innate Pharma SA are DRRX, VCNX, VNE, CLDX, and PULM.
- IPHA's SEC filings can be seen here. And to visit Innate Pharma SA's official web site, go to www.innate-pharma.com.
IPHA Stock Price Chart Interactive Chart >
IPHA Price/Volume Stats
| Current price | $5.16 | 52-week high | $8.24 |
| Prev. close | $5.02 | 52-week low | $3.30 |
| Day low | $4.99 | Volume | 13,100 |
| Day high | $5.30 | Avg. volume | 19,202 |
| 50-day MA | $4.19 | Dividend yield | N/A |
| 200-day MA | $5.85 | Market Cap | 407.54M |
INNATE PHARMA SA (IPHA) Company Bio
Innate Pharma SA is a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. Its products include immunotherapy drugs and monoclonal antibodies. The Immunotherapy drugs are designated for cancer and inflammatory diseases. The Monoclonal antibodies targets receptors and pathways controlling the activation of innate immunity cells.
Loading social stream, please wait...